- Home
- AEC vs TNYA Comparison
AEC vs TNYA Comparison
Compare AEC & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEC | TNYA |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 157.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEC | TNYA |
|---|---|---|
| Price | $6.71 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 136.9K | ★ 4.2M |
| Earning Date | 05-01-2015 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $0.36 |
| 52 Week High | $12.49 | $2.35 |
Technical Indicators
Market Signals| Indicator | AEC | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 40.89 |
| Support Level | $6.03 | $0.65 |
| Resistance Level | $7.14 | $0.86 |
| Average True Range (ATR) | 0.78 | 0.08 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 5.23 | 7.67 |
Price Performance
Historical ComparisonAbout AEC Anfield Energy Inc.
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One. The company's geographical segments are Canada and the United States.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.